Medtronic Aktie
| 84,08USD | -0,93USD | -1,09% |
WKN DE: A14M2J / ISIN: IE00BTN1Y115
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,92 |
| The Vanguard Group, Inc. | 9,87 |
| Vanguard Group, Inc. (Subfiler) | 9,16 |
| State Street Corp. | 4,74 |
| Vanguard Total Stock Market ETF | 3,17 |
| BlackRock Fund Advisors | 2,87 |
| Vanguard 500 Index Fund | 2,62 |
| Capital Research & Management Co. (Global Investors) | 2,54 |
| BlackRock Institutional Trust Co. NA | 2,31 |
| Geode Capital Management LLC | 2,06 |
| Massachusetts Financial Services Co. | 1,90 |
| JPMorgan Investment Management, Inc. | 1,65 |
| Wellington Management Co. LLP (Wellington Breakout) | 1,37 |
| Fidelity 500 Index Fund | 1,23 |
| SPDR S&P 500 ETF Trust | 1,21 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 90 000 | 90 000 | 95 000 | 95 000 | 95 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,32 | 0,33 | 0,33 | 0,33 | 0,34 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 22 031 | 22 548 | 23 059 | 21 675 | 21 935 |
| Summe Anlagevermögen | 68 658 | 70 535 | 67 922 | 69 273 | 68 046 |
| Summe Aktiva | 90 689 | 93 083 | 90 981 | 90 948 | 89 981 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 25 742 | 27 404 | 24 984 | 25 413 | 26 047 |
| Summe Fremdkapital | 39 817 | 41 481 | 38 260 | 39 283 | 39 561 |
| Summe Eigenkapital | 50 872 | 51 602 | 52 722 | 51 665 | 50 420 |
| Summe Passiva | 90 689 | 93 083 | 90 982 | 90 948 | 89 981 |
Adresse
| Parkmore Business Park West, 2 Galway | |
| Telefon | +353 (1) 438-1700 |
| Internet | http://www.medtronic.com |
Management
|
Alexandra Clyde
SVP-Global Health Economics & Policy |
|
Andrea J. Goldsmith
Independent Director |
|
Bob Hopkins
Senior Vice President & Head-Global Strategy |
|
Craig Arnold
Lead Independent Director |
|
Elizabeth G. Nabel
Independent Director |
|
Gary Corona
CFO, SVP-Global Financial Planning & Analysis |
|
Geoffrey Straub Martha
Chairman & Chief Executive Officer |
|
Gregory L. Smith
Executive VP-Global Operations & Supply Chain |
|
Gregory P. Lewis
Independent Director |
|
Harry Skip Kiil
President-Cranial & Spinal Technologies |
|
Ivan K. Fong
Secretary, Executive VP & General Counsel |
|
Jennifer M. Kirk
Chief Accounting Officer, SVP & Global Controller |
|
Kelly Wei
Vice President-Corporate Strategy |
|
Kendall J. Powell
Independent Director |
|
Kenneth E. Washington
SVP, Director-Technology & Innovation |
|
Kevin E. Lofton
Independent Director |
|
Laura Mauri
Director-Scientific, Clinical & Regulatory Officer |
|
Lidia L. Fonseca
Independent Director |
|
Matthew Walter
Chief Human Resources Officer |
|
Mira Sahney
President-Pelvic Health Operating Unit |
|
Que Thanh Dallara
EVP & President-Global Diabetes Operating Unit |
|
Raman Venkatesh
Chief Sustainability Officer & Vice President |
|
Randall J. Hogan
Independent Director |
|
Ryan Weispfenning
Vice President & Head-Investor Relations |
|
Sally Saba
Chief Inclusion & Diversity Officer |
|
Scott C. Donnelly
Independent Director |
|
Scott Cundy
Chief Quality Officer & Senior Vice President |
|
Sean Salmon
EVP, President-Cardiovascular Portfolio |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
